Additionally, ILC tumor histology was not significantly associated with survival: as compared to classical ILC tumor histology, mixed ILC tumor histology predicted similar survival in both the group who received Anti-Her2 therapy (HR: 0.84, 95% CI: 0.62–1.15, p=0.28) and the group who didn't receive Anti-Her2 therapy (HR: 1.03, 95% CI: 0.74–1.43, p=0.87) (Table 3). The gene discussed is ERBB2; the disease is neoplasm.